LONDON: Researchers in the UK are using new methods for rapid development and mass manufacturing mRNA vaccines and lower medical costs COVID-19 and a range of other diseases.
The research project will boost the capacity of the UK and the world to rapidly develop new vaccines in response new version of covid-19 And future pandemics too.
In a non-emergency, the new production technology will give developers and manufacturers access to state-of-the-art processes needed to produce new vaccines and treatments for other major diseases such as cancer, metabolic disorders, heart conditions and autoimmune diseases. Increasingly, the University of Sheffield said in a statement on Sunday.
“The vaccines produced for COVID-19 have shown us what is possible using RNA technology. In one of the greatest scientific achievements of our generation, RNA technology has demonstrated the potential to change the timeline for developing and delivering a vaccine from years to months,” said lead researcher Zoltan Kiss from the University’s Department of Chemical and Biological Engineering. he said.
“This is a versatile and transformative technology that can be used to develop and mass-produce vaccines and treatments for other diseases. To achieve this, we need to ensure that researchers around the world have access to Have access to the latest, state-of-the-art RNA manufacturing processes to support our research, development and large-scale production programs.
The new vaccine production unit at the university will form a central part of Welcome Leap’s R3 program, which aims to establish a network of vaccine manufacturing facilities around the world that are designed, developed and produced to increase the number of RNA-based therapies. went. The year.
The network will also be able to rapidly produce new vaccines if needed in response to future pandemics.
“CoVID-19 has shown us how important it is to be prepared so that we can respond to the pandemic quickly. The way we can make vaccines and distribute these production processes around the world will enable us to respond to future pandemics much faster and much more effectively,” Kiss said.
“In non-pandemic times, these production processes implemented around the world can be used to produce the vaccines and therapeutic candidates we desperately need against a wide range of diseases,” said the lead researcher.
The research project will boost the capacity of the UK and the world to rapidly develop new vaccines in response new version of covid-19 And future pandemics too.
In a non-emergency, the new production technology will give developers and manufacturers access to state-of-the-art processes needed to produce new vaccines and treatments for other major diseases such as cancer, metabolic disorders, heart conditions and autoimmune diseases. Increasingly, the University of Sheffield said in a statement on Sunday.
“The vaccines produced for COVID-19 have shown us what is possible using RNA technology. In one of the greatest scientific achievements of our generation, RNA technology has demonstrated the potential to change the timeline for developing and delivering a vaccine from years to months,” said lead researcher Zoltan Kiss from the University’s Department of Chemical and Biological Engineering. he said.
“This is a versatile and transformative technology that can be used to develop and mass-produce vaccines and treatments for other diseases. To achieve this, we need to ensure that researchers around the world have access to Have access to the latest, state-of-the-art RNA manufacturing processes to support our research, development and large-scale production programs.
The new vaccine production unit at the university will form a central part of Welcome Leap’s R3 program, which aims to establish a network of vaccine manufacturing facilities around the world that are designed, developed and produced to increase the number of RNA-based therapies. went. The year.
The network will also be able to rapidly produce new vaccines if needed in response to future pandemics.
“CoVID-19 has shown us how important it is to be prepared so that we can respond to the pandemic quickly. The way we can make vaccines and distribute these production processes around the world will enable us to respond to future pandemics much faster and much more effectively,” Kiss said.
“In non-pandemic times, these production processes implemented around the world can be used to produce the vaccines and therapeutic candidates we desperately need against a wide range of diseases,” said the lead researcher.
,